Viewing nowCombinationLovatitan Tablet 5/160 mg
Valsartan 160mg · Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.

MFDS item code 201404990 · Approved 2014.10.28 · Insurance code 668902900
Treatment of hypertension and heart failure, improvement of dyslipidemia, and prevention of atherosclerosis and cardiovascular risk
This medication is used for patients who require both valsartan and rosuvastatin at the same time. Valsartan helps reduce the risk of mortality from essential hypertension, heart failure, and post-myocardial infarction. It is particularly effective for heart failure patients intolerant to ACE inhibitors. Rosuvastatin is used for dyslipidemias such as hypercholesterolemia, lowering total and LDL cholesterol levels, thereby delaying the progression of atherosclerosis. It also reduces the risk of cardiovascular disease and decreases the likelihood of stroke and myocardial infarction. Thus, this medication is used for the treatment of cardiovascular diseases such as hypertension, heart failure, and hyperlipidemia.
This medication is administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medication be taken at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, an oral dose of valsartan 80 mg once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years and older): Initiate treatment with this medication at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with this medication at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with this medication at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with this medication at 40 mg once daily; the dose should not exceed 80 mg once daily. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consideration should be given to reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple concomitant administration of this medication with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg per dose twice daily, followed by dose increases over several weeks to 40 mg, 80 mg, and 160 mg per dose twice daily, as tolerated by the patient. Consider dose reduction if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher. However, do not administer this medication to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medication should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Before and during treatment with this medication, patients should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medication may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which provides adequate control for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medication to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, they may be switched to this medication (a combination product containing the same amount of each active ingredient) for convenience.
6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the 2nd and 3rd trimesters, so discontinuation should be immediate upon confirmation of pregnancy. It should not be used in patients with allergic reactions, severe liver dysfunction, severe kidney failure, or specific genetic diseases. Caution is necessary for elderly patients, patients with high serum potassium levels, and patients with liver impairment while taking this medication, and regular liver function tests are required. If symptoms of muscle pain or weakness occur, consult a doctor immediately, and patients at high risk of muscle damage should be tested for muscle enzymes before and during treatment. This medication may interact with other antihypertensive agents, diuretics, potassium-sparing agents, etc., so be sure to inform the doctor of any medications being taken concurrently. Dizziness may occur when driving or operating machinery, so caution is advised, particularly when starting treatment or changing dosage. This medication can affect liver and kidney function, so regular blood tests and physical exams are necessary. Women of childbearing potential should use appropriate contraception while taking this medication and should consult a doctor if planning pregnancy or if pregnancy is confirmed. Use of this medication during breastfeeding is not recommended; if it must be taken, breastfeeding should be discontinued. In the event of overdose, severe hypotension and altered consciousness may occur, so immediate medical attention is necessary, and treatment should be based on symptoms as there is no specific antidote. This medication should be kept out of reach of children and should not be transferred to other containers.
Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial swelling, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver aminotransferase levels, increased serum creatine phosphokinase, elevated serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory decline, anxiety, upper respiratory infection, pharyngitis, tonsillitis, spinal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes, diabetes complications, leg fracture, spinal fracture, fracture, skin neoplasm, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin tumor-like condition, herpes zoster, intervertebral disc herniation, hemoptysis, sputum disorders, bronchitis, paresthesia, hoarseness, gastroesophageal reflux, diverticulitis, stomatitis, gastritis, carpal tunnel syndrome, chills, facial flushing, increased blood glucose, elevated triglycerides, increased blood pressure, worsening hypertension, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified dermatitis, localized skin reaction, palpitations, worsening angina, auditory abnormalities, hypersensitive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, headache, dizziness, constipation, abdominal pain, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, eosinophilia with systemic symptoms associated drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, myasthenia gravis, ocular myasthenia, hypotension, orthostatic dizziness, orthostatic hypotension, renal function impairment, hyperkalemia, angioedema, syncope, vascular edema, erythema, itching, serum sickness, vasculitis, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, agranulocytosis, leukopenia, thrombocytopenia, reduction in erythrocyte volume, decreased hemoglobin, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, colic, arthralgia, hypotension, blood pressure decrease, reduction in blood pressure, syncope due to blood pressure reduction, loss of consciousness due to blood pressure reduction, shock due to blood pressure reduction, tachycardia, bradycardia due to parasympathetic stimulation
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light, so it should be stored in a tightly sealed container that prevents light exposure. Additionally, it is recommended to store it at a temperature between 1 and 30 degrees Celsius.
Bright orange oval film-coated tablet
56 tablets (14 tablets/PTP x 4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationValsartan 160mg · Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 160mg · Rosuvastatin Calcium Micronized 20.8mg
Tablet · Prescription medication · Combination
LG Chemical Co., Ltd.
CombinationValsartan 80mg · Rosuvastatin Calcium Micronized 20.8mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 160mg · Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 80mg · Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 80mg · Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication · Combination
LG Chemical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.